Subcutaneous atezolizumab for the treatment of non-small cell lung cancer
Subcutaneous immunotherapy delivers the same cancer-fighting benefits as infusions while improving convenience and reducing clinic burden.
This review summarizes evidence for subcutaneous atezolizumab delivery in NSCLC, highlighting equivalent pharmacokinetics and efficacy compared to intravenous administration. The subcutaneous route could improve patient experience and reduce healthcare resource utilization.
What the study was
- Study design
- Narrative review
- Population
- NSCLC patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Therapeutic Delivery
Why it surfaced
Relevant review of drug delivery innovation in immunotherapy but not novel primary data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.